News | Antiplatelet and Anticoagulation Therapies | August 16, 2017

Meta-Analysis Evaluates the Effect of Post-PCI Bivalirudin on Adverse Clinical Events

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.

August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivalirudin doses on net adverse clinical events (NACEs) and mortality. Patients recovering from PCI with bivalirudin are at a lower risk of bleeding, but also suffer an increased risk of acute stent thrombosis (ST). Bivalirudin is a direct thrombin inhibitor that can prevent blood clots during and after an angioplasty procedure. Previous research concluded that continuing bivalirudin infusion at full doses for four hours post-PCI eliminates acute ST risk while maintaining the bleeding benefit. The results of the current study determined that full-dose bivalirudin infusion post-PCI for four hours is also associated with improved NACEs and all-cause mortality. Details of the entire study are outlined in the Editor’s Choice article of the August 2017 issue of Catheterization and Cardiovascular Interventions.  

Researchers analyzed randomized-clinical trials (RCTs) to gather results. The data was separated into two groups: (1) patients treated with bivalirudin and (2) patients treated with unfractionated heparin (UFH). The bivalirudin arm was divided based on post-PCI bivalirudin dosage; The Biv-Full group received 1.75 mg/kg/h, the BivLow group, 0.25 mg/kg/h and the Biv-No group, none.  

“For many years, heparin was the only anticoagulant available for primary PCI,” said Rahman Shah, M.D., FSCAI, of the division of cardiovascular medicine at the University of Tennessee Health Science Center. “However, once a lower risk of bleeding was found with bivalirudin, many cardiologists started using it preferentially over heparin. Once the acute stent thrombosis risk with bivalirudin was well-publicized, many physicians returned to using heparin. With this research, we show that for patients undergoing primary PCI, bivalirudin [with four-hour post-PCI infusion at full dose] might be the safest and most effective anticoagulation because it is associated not only with decreased risk of bleeding and net adverse clinical event events, but also improved mortality.”

Six RCTs and 16,842 patients met the criteria for inclusion. Bivalirudin exhibited an improvement in 30-day all-cause mortality by 35 percent and cardiac mortality by 32 percent, but did not yield a NACE rate better than that achieved with UFH. Subgroup analysis showed the Biv-Full group had a 46 percent lower NACE rate and 47 percent lower all-cause mortality than UFH. These effects were not seen in the other two groups. The Biv-Full group yielded the best treatment efficacy overall.

“Our findings are consistent with recent changes to the bivalirudin package insert by the FDA,” Shah continued. “Therefore, if bivalirudin-based anticoagulation is used during primary PCI, it should be continued for at least four hours [at full dose] post-PCI. Ongoing trials such as SWEDEHEART (NCT02311231), which mandates full-dose bivalirudin post-PCI in patients with acute coronary syndrome, will provide additional insights into this topic.”

The authors of “Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Net Adverse Clinical Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis of Randomized Controlled Trials” include Rahman Shah, M.D., FSCAI; Khalid Matin, M.D.; Kelly C. Rogers, Pharm.D; and Sunil V. Rao, M.D., FSCAI.

For more information: www.scai.org/CCI

Related Bivalirudin Content:

No Difference Adverse Events When Comparing Anticoagulants

Study Finds Blood Clot Prevention Medications Equally Safe and Effective for PCI Patients

Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR

 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init